Clinical Trial Update: Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies [Phase 1]

View source ↗

Summary

Phase I, open-label, dose-escalation trial of AZD4877 in hematologic malignancies focusing on lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• AZD4877

Snippet

Sponsor: AstraZeneca | Conditions: Lymphoma | Phase 1 | Status: TERMINATED